News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ThromboGenics NV (TBGNF) Business Update



5/16/2013 10:29:35 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LEUVEN, Belgium, May 16, 2013 /PRNewswire/ - ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic and oncology medicines, today issued a business and financial update ending 30 April, 2013.

During 2013, ThromboGenics delivered a number of key corporate milestones, the most important of which was the launch of JETREA® (ocriplasmin) in the US on 14 January via its own commercial organization. ThromboGenics' partner outside the US, Alcon, launched JETREA® in the UK and Germany after its approval by the European Commission in March 2013. The EU approval and the launch of JETREA® in the UK led to ThromboGenics receiving two equal milestones from Alcon amounting to a total of €90 million.

Help employers find you! Check out all the jobs and post your resume.




comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES